Market Reviews

Orthopedic Public Companies Grow 2.6% YoY in Quarter

Orthopedic Public Companies Grow 2.6% YoY in Quarter
The second quarter of 2019 brought incremental improvement over the first. Stryker and Medtronic saw revenue growth in the mid-single digits, Smith Nephew performed at 1.6% and DePuy Synthes and Zimmer Biomet experienced a year-over-year loss. Price pressure was a common theme in the quarter for many companies, as it offset some gains made from increased surgical volumes for the reporting period.

Member-Only Content

SUBSCRIBE Login

Orthopedic Sales in Line with Seasonal Expectations for 1Q19

Orthopedic Sales in Line with Seasonal Expectations for 1Q19
The first quarter of 2019 brought modest growth to the orthopedic market, as expected seasonal softness and more competition in digital surgery platforms slowed sales for some of the largest players. The 25 companies covered in this article had combined total orthopedic sales of $8.7 billion, growing just 1.1% versus the prior year. While the top two players, DePuy Synthes and Zimmer Biomet, both saw -2% growth, the quarter did feature strong performances by Medtronic (+5%) and Wright Medical (+16%) among the larger players.

Member-Only Content

SUBSCRIBE Login

Orthopedic Industry Revenue Reaches $51 Billion in 2018

Orthopedic Industry Revenue Reaches $51 Billion in 2018
According to our estimates published in THE ORTHOPAEDIC INUSTRY ANNUAL REPORT, orthopedic industry revenue reached $51 billion worldwide in 2018 and grew 3.5% over 2017. Results were mixed among the largest companies as some stumbled operationally while others overperformed, due in part to early adoption of technology and entry into high-growth segments. Common strategic themes present in 2018 that will continue as part of the industry's narrative in 2019 and beyond include connected ecosystems of products, flagship technology (e.g. robotics), portfolio-wide pull through and a growing shift to outpatient procedures.

Member-Only Content

SUBSCRIBE Login

3Q18 and 9 Month 2018 Performance Highlights for Public Companies

3Q18 and 9 Month 2018 Performance Highlights for Public Companies
Several companies noted increased case volume in the third quarter, likely driven by a strong U.S. economy leading to more widespread insurance coverage and patients able to pay for elective procedures. Sales results were mixed outside of the U.S., particularly in the EMEA region where reimbursement issues continue to be a challenge in the U.K. and Germany. Companies generally performed well, however, in emerging markets.

Member-Only Content

SUBSCRIBE Login